The protein TIP-1 appears to be a novel prognostic marker for glioblastoma and may be a good therapeutic target for disrupting tumor-driven blood vessel development.
AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.
Even relatively low levels of in utero alcohol exposure impact fetal brain development, and the effects last into adulthood, study finds.
Vanderbilt’s Bill Wilkerson Center and the Department of Hearing and Speech Sciences are offering new interdisciplinary outpatient programs for children ages 3 to 21 who have experienced a traumatic brain injury (TBI).
An analysis of Amish populations revealed novel risk genes for late-onset Alzheimer disease.
Deep brain stimulation used to treat Parkinson’s disease may impair some aspects of language processing, a recent study suggests.